Dual MAPK Inhibition Is an Effective Therapeutic Strategy for a Subset of Class II BRAF Mutant MelanomasMatthew Dankner, April A. N. Rose, David Hogg et al.|Clinical Cancer Research|2018Cited by 76
Intrathecal trastuzumab versus alternate routes of delivery for HER2-targeted therapies in patients with HER2+ breast cancer leptomeningeal metastasesAnna-Maria Lazaratos, Matthew Dankner, Sarah M. Maritan et al.|The Breast|2023Cited by 25
Abstract B056: Non-V600 BRAF mutations in melanoma: actionable targets for rational drug combinationsApril A. N. Rose, Peter M. Siegel, Matthew Dankner et al.|Molecular Cancer Therapeutics|2018Cited by 1
Dual MAPK inhibition (dMAPKi) as an effective therapeutic strategy for class II BRAF mutant (mt) metastatic melanoma (MM).Matthew Dankner, April A. N. Rose, Mathieu Lajoie et al.|Journal of Clinical Oncology|2018Cited by 0
A systematic review and meta-analysis of intrathecal versus alternate routes of delivery for HER2-targeted therapies in patients with HER2+ breast cancer leptomeningeal metastases.Anna-Maria Lazaratos, Matthew Dankner, Sarah M. Maritan et al.|Journal of Clinical Oncology|2023Cited by 0